Clinical trial

An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC

NCT07669610

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention SHR- A1811 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention SHR-A1811+BEV Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-10-01

PhasePHASE3

Conditions

Breast Cancerverified · MONDO: breast cancer

Triple Negative Breast Cancer (TNBC)unresolved

Interventions

SHR- A1811DRUG

SHR-A1811+BEVDRUG

Sponsors & collaborators

Fudan Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07669610 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.